Helmholtz Centre for Infection Research

What Helmholtz Centre for Infection Research does

Helmholtz Centre for Infection Research (HZI) is a publicly funded, non-university research institution founded in 1965 and headquartered in Braunschweig, Germany. It operates as a member of the Helmholtz-Gemeinschaft Deutscher Forschungszentren, the largest German research organization, and runs an integrated network of six specialized sites: HZI Campus and BRICS (Braunschweig), CSSB (Hamburg), TWINCORE/CiiM/CRC (Hannover), HIPS (Saarbrücken), HIRI (Würzburg), and HIOH (Greifswald). Core research spans microbiology, immunology, virology, pharmaceutical sciences, bioinformatics, and translational medicine, with a stated mission of understanding infections and combating pathogens, including a dedicated focus on antimicrobial resistance, novel anti-infectives from natural products, RNA-based infection biology, and individualized infection medicine.

HZI's output is research-driven rather than commercial-product-driven. Its revenue base is anchored by federal and state government Grundfinanzierung (base funding) channeled through the Helmholtz Association, supplemented by third-party competitive grants (including EU programs and CARB-X awards) and a small but growing technology-transfer/licensing stream from spin-offs and industry partnerships (e.g., the Beiersdorf-HIPS skin microbiome collaboration announced January 2026, and Phyton Biotech's Corallopyronin A manufacturing partnership). The institution manages a publication database of over 10,000 scientific outputs, trains more than 300 doctoral researchers across dedicated graduate programs, and operates the NAKO German National Cohort study site in Hannover. AI/ML capabilities are embedded in research workflows, including machine-learning models for antimicrobial resistance prediction, bioinformatics pipelines for genomic and single-cell sequencing data, and text/NLP methods applied to its publication corpus.

HZI serves academic research collaborators, pharmaceutical and biotech industry partners (drug discovery, technology transfer, contract research, licensing), federal and state health authorities (epidemiology, population health, NAKO), and clinical partners (university hospitals running early-phase trials via TWINCORE, CRC, and CiiM). The organization is governed by a supervisory board including federal and state ministry representatives and led by Scientific Director Prof. Josef Penninger and Administrative Director Christian Scherf.

Name

Helmholtz Centre for Infection Research

Legal name

Helmholtz-Zentrum für Infektionsforschung GmbH

Website

https://helmholtz-hzi.de

Company type

Private

Founded year

1965

Operating status

Operating

Headcount range

501–1,000 employees

Short description

HZI is a publicly funded German infection research institution operating six specialized sites under the Helmholtz Association, delivering anti-infective drug discovery, RNA-based infection biology, clinical translation, and epidemiology for academic, industry, and government health partners.

Ownership category

akta.pro rank

Product category

Infection Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Healthcare-Associated Infection (HAI) & Antimicrobial Resistance (AMR) Surveillance (HLAJABAH), Laboratory-Based Surveillance & Genomic Epidemiology (WGS/NGS) (HLAJABAC)

Keywords

• Infection research
• Pharmaceutical research
• Antimicrobial drug discovery
• Translational medicine
• Epidemiological research

Headquarters

HQ city

Braunschweig

HQ country

Germany

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Government Base Funding: HZI receives core funding from the German federal government and state governments as a member of the Helmholtz-Gemeinschaft Deutscher Forschungszentren. The base funding (Grundfinanzierung) was Mio. EUR in 2025 as displayed on the website.
2. Third-Party Research Funding: Additional research funding from competitive grants, EU research programs, industry partnerships, and collaborative research projects with other institutions
3. Technology Transfer and Licensing: Revenue from technology transfer, spin-off companies, and licensing of research outcomes to pharmaceutical industry partners

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

HZI conducts basic and translational infection research across six specialized German sites, delivering anti-infective drug discovery, RNA-based infection biology, pharmaceutical sciences, clinical trials, and epidemiological studies. It operates research institutes for pharmaceutical research (HIPS), RNA-based infection research (HIRI), experimental and clinical infection research (TWINCORE), individualized infection medicine (CiiM), and clinical trials (CRC), and runs a publication database, a graduate school with over 300 doctoral students, and citizen science programs.

Product overview

The Helmholtz Centre for Infection Research (HZI) is a multi-site German research institution comprising a central campus in Braunschweig and six specialized institutes across Germany: HIPS (pharmaceutical research, Saarbrücken), HIRI (RNA-based infection research, Würzburg), TWINCORE (experimental and clinical infection research, Hannover), CiiM (individualized infection medicine, Hannover), CRC (clinical research and NAKO health study, Hannover), and HIOH (One Health, Greifswald). The institution operates a publication database with over 10,000 research contributions and offers doctoral education through its graduate school. HZI focuses on understanding and combating infectious diseases through interdisciplinary research spanning drug discovery, genomics, clinical trials, epidemiology, and therapeutic development.

Differentiator

Problem solved

Functional benefit

Products and services

• HIRI - Helmholtz Institute for RNA-based Infection Research The first institution worldwide combining RNA research with infection biology. Based at the Würzburg Medical Campus with Julius-Maximilians-Universität Würzburg, HIRI develops RNA-based therapeutic and diagnostic approaches for human infections, including single-cell sequencing and virus-host interaction studies.
• HIPS - Helmholtz Institute for Pharmaceutical Research Saarland Germany's first public research institute explicitly devoted to pharmaceutical sciences. HIPS discovers novel anti-infectives from natural products (especially soil bacteria), optimizes natural product producers, develops drug delivery systems across biological barriers, and partners with Saarland University.
• TWINCORE - Centre for Experimental and Clinical Infection Research Translational research center in Hannover where medical personnel and basic research scientists work side by side, bridging laboratory discoveries with clinical applications for patients. Joint facility with Hannover Medical School.
• CiiM - Centre for Individualised Infection Medicine Joint venture with Hannover Medical School developing individualized approaches to infectious disease management, identifying patient-specific parameters that influence infection progression and translating findings into optimized patient care.
• CRC - Clinical Research Center Hannover Shared research facility where HZI, Fraunhofer ITEM, and Hannover Medical School conduct early clinical trials of new drugs and medical devices, and coordinate the NAKO German National Cohort health study.
• HZI Publication Database Searchable database containing over 10,000 publications from HZI researchers, allowing targeted searches for scientific contributions across all research areas.
• HZI Graduate School and PhD Programs Comprehensive doctoral programs including a dedicated Graduate School, PhD Programme in Epidemiology, and the DO IT doctoral initiative, offering over 300 doctoral researchers training in infection research.
• MICROBELIX Citizen Science Project Citizen science project where HIPS researchers enlist public participation to explore soil bacteria biodiversity for drug discovery, treating the soil as a microbial treasure trove for novel anti-infective compounds.
• NAKO German National Cohort Germany's largest nationwide health study, with HZI involvement, investigating origins of common illnesses including cardiovascular diseases, cancer, diabetes, dementia, infections, and immune system disorders; involves 200,000+ participants with biospecimen collection and long-term follow-up.

Quantifiable outcome

• Over 10,000 publications in research database
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Beiersdorf AGcoreStrategic or Co-development Partner · 22 January 2026Exclusive research partnership with HIPS to investigate how the skin microbiome contributes to maintaining healthy skin. The collaboration builds on large microbiome and genomic datasets originally developed for infectious disease research, includes two funded projects with room for expansion, and could strengthen Beiersdorf's innovation pipeline by grounding future skincare concepts in advanced microbiome science.
• Saarland UniversitycoreStrategic or Co-development PartnerCo-founding partner of HIPS (Helmholtz Institute for Pharmaceutical Research Saarland) established in August 2009. Provides academic integration and access to pharmaceutical sciences expertise.
• Julius-Maximilians-Universität Würzburg (JMU)coreStrategic or Co-development PartnerCo-founding partner of HIRI (Helmholtz Institute for RNA-based Infection Research) established in May 2017. HIRI is located on the Würzburg Medical Campus.
• Hannover Medical School (MHH)coreStrategic or Co-development PartnerPartner in TWINCORE, CRC, and CiiM facilities. MHH investigators conduct early clinical trials and collaborate on infection research.
• Fraunhofer ITEMcoreStrategic or Co-development PartnerPartner in CRC Hannover facility, conducting early clinical trials of new drugs and medical devices alongside HZI researchers.
• Phyton BiotechminorStrategic or Co-development PartnerSuccessful technology transfer partnership for manufacturing process of Corallopyronin A (CorA), a novel anti-infective agent for neglected tropical diseases.
• Uppsala UniversityminorStrategic or Co-development PartnerResearch collaboration with HIRI on culturing mini-organs to study aggressive bacteria like Shigella.
• Helmholtz-Gemeinschaft Deutscher Forschungszentren e.V.coreStrategic or Co-development PartnerHZI is a member of the Helmholtz Association, the largest research organization in Germany, providing strategic framework and collaboration opportunities.
• Technische Universität BraunschweigcoreStrategic or Co-development PartnerPartner in BRICS (Braunschweig Integrated Centre of Systems Biology) and co-awarder of Inhoffen Medal with Friends of HZI.

Scale indicators5 records

Recent moves2 records

Direct peers

• Max Planck Institute for Infection Biology: Berlin-based Max Planck Institute dedicated to infection biology and immunology. Direct peer as a German public research institute with overlapping focus on bacterial/viral pathogenesis, host-pathogen interaction, and translational immunology.
• Institut Pasteur: French non-profit foundation dedicated to infectious disease research, epidemiology, and public health. Direct peer in mission and structure (public research foundation focused on infectious diseases with global public-health mandate), though based in France.
• Robert Koch Institute: German federal government agency for disease surveillance, epidemiology, and infectious disease research. Direct peer operating in Germany with shared focus on AMR, infectious disease surveillance, and public-health intervention research.
• Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health): German federal research institute for animal health and zoonotic diseases. Direct peer sharing the One Health mission with HZI's HIOH institute, covering zoonotic infections, epidemiology, and pandemic preparedness.
• Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI): German Leibniz Institute focused on natural product chemistry and infection biology in Jena. Direct peer with strong overlap in microbial natural product discovery, anti-infective drug development, and infection biology.

Broad incumbents

• European Molecular Biology Laboratory (EMBL): Intergovernmental research organization in molecular life sciences with sites across Europe. Broad incumbent in life-science R&D; comparable to HZI in genomics, structural biology, and bioinformatics infrastructure though broader in scope.
• Wellcome Sanger Institute: UK-based genomic and infection research institute, strong in pathogen genomics and AMR surveillance. Broad incumbent in genomic epidemiology and infectious disease research; comparable scale and public funding model.
• The Francis Crick Institute: UK biomedical discovery institute covering infection and immunity alongside cancer and neuroscience. Broad incumbent with overlapping infection/immunology research portfolio and comparable scale (~1,500 staff).
• Broad Institute of MIT and Harvard: US genomics and infectious disease research institute with strong capabilities in pathogen genomics, AMR, and drug resistance. Broad incumbent with comparable genomic epidemiology, AI/ML for AMR prediction, and translational capabilities.
• National Institute of Allergy and Infectious Diseases (NIAID): US NIH institute for allergy and infectious disease research, the largest single public funder of infection research globally. Broad incumbent covering basic and translational infectious disease research at much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/helmholtz_hzi
• YouTubeyoutube.com/@HelmholtzHZI
• Facebookfacebook.com/helmholtz.hzi
• LinkedInlinkedin.com/company/helmholtz-centre-for-infection-research
• Instagraminstagram.com/helmholtz_hzi

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helmholtz Centre for Infection Research